Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Artivion (AORT)

Artivion amends Endospan deal, adds up to $25 million in loans, lowers purchase payment

Neutral Impact 3 of 5 m&a Written later

Artivion amended its 2019 loan and purchase option agreements with Endospan Ltd., a privately held developer of the NEXUS stent graft system. Artivion will provide up to $25 million in additional secured loans, and the option's upfront payment is cut from $250 million to $175 million, or $135 million after loan offset. The company does not expect the amended agreement to have a material impact on its full-year 2024 guidance, and the option takes effect only if Artivion exercises it.

Key points

  • Up to $25 million in new secured loans to Endospan, in tranches of $7 million, $10 million and $8 million; first tranche to be funded as soon as practicable
  • Loans bear 5% annual interest and are due on the earlier of a third-party acquisition of Endospan or December 31, 2027
  • Upfront purchase payment reduced from $250 million to $175 million, or $135 million inclusive of loan offset; $100 million minimum earnout eliminated
  • Company does not anticipate a material impact on full-year 2024 financial guidance

The filing

CompanyArtivion (AORT)
Form8-K, current report
Filed with the SECJul 1, 2024, 4:13 PM ET
Accession number0000784199-24-000207

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.